Globe Newswire

NEW YORK, June 25, 2022 (GLOBE NEWSWIRE) -- Mercer International Inc. (“Mercer” or the “Company”) (Nasdaq: MERC) is deeply saddened to announce that an employee has passed away at its Rosenthal mill in Germany on June 25, 2022. Mercer and local authorities conducted an investigation and so far determined that the tragic loss was not work related. Mercer’s emergency procedures were immediately activated, local authorities were notified and industrial safety... (continue reading...)

• Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron
• Geometric mean ratios for Omicron neutralizing antibody response consistent with regulatory requirement of superiority
• Preliminary laboratory studies demonstrate both Omicron-adapted candidates... (continue reading...)

• Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron
• Geometric mean ratios for Omicron neutralizing antibody response consistent with regulatory requirement of superiority
• Preliminary laboratory studies demonstrate both Omicron-adapted candidates... (continue reading...)

• Late-breaking data from the double-blind portion of the noninvasive Phase 3 MAESTRO NAFLD-1 study show resmetirom to be safe and well-tolerated and to reduce liver fat, fibrosis measures on FibroScan and MRE, and liver enzymes, as well as multiple atherogenic lipids
• In NASH patients with well-compensated cirrhosis, resmetirom:
  • was safe and well tolerated
  • reduced liver fat, LDL-C, and other atherogenic lipids
  • reduced noninvasive measures of liver fibrosis and liver... (continue reading...)

– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals –

– Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June –

SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical... (continue reading...)